Dihexa (PNB-0408): Structure, Solubility, Paper Controversy & Research Status in 2026

Introduction#

Dihexa (PNB-0408) is a synthetic oligopeptide derived from angiotensin IV that has attracted intense interest in cognitive enhancement circles -- and equally intense scrutiny from the scientific community. Developed at Washington State University by Joseph Harding and colleagues, dihexa was designed as a metabolically stable, orally bioavailable compound that could cross the blood-brain barrier and potentiate hepatocyte growth factor (HGF) signaling at the c-Met receptor.

The compound's story is unusual among research peptides. Claims of neurotrophic potency "10 million times greater than BDNF" propelled it into nootropic forums and gray-market peptide catalogs. But behind those claims lies a more complicated reality: a retracted paper, a revoked PhD, a failed clinical trial for a related drug, and an ongoing debate about whether activating an oncogenic signaling pathway in the brain is a scientifically sound approach to treating neurodegeneration.

This review examines where dihexa research actually stands in 2026, covering its chemical properties, the paper retraction controversy, the fate of the clinical pipeline, and the unresolved safety questions that define this compound's risk profile.

Chemical Structure and Properties#

Dihexa is a modified dipeptide with the systematic name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It has a molecular weight of 504.66 Da and the molecular formula C27H44N4O5 (CAS: 1401708-83-5). Unlike most neuropeptides, which are longer polypeptide chains, dihexa is a compact peptidomimetic built around a minimized pharmacophore.

Structural Design#

The compound consists of three components engineered for metabolic stability:

• N-terminal hexanoic acid cap: A six-carbon aliphatic chain that protects against aminopeptidase degradation, replacing the Val-Tyr N-terminal portion of the parent angiotensin IV hexapeptide (VYIHPF).
• Central Tyr-Ile dipeptide core: The minimal pharmacophore required for HGF binding activity, retained from the angiotensin IV sequence.
• C-terminal 6-aminohexanoic amide: A non-natural modification providing carboxypeptidase resistance while maintaining the spatial orientation needed for target interaction.

This design reduces molecular weight from approximately 774 Da (native angiotensin IV) to 505 Da -- well below the typical oral bioavailability threshold for peptidomimetics -- while providing resistance to enzymatic degradation that the parent hexapeptide lacks entirely.

Solubility Profile#

Dihexa is a highly lipophilic compound with an octanol/water partition coefficient of approximately 178, which explains both its oral absorption characteristics and its limited aqueous solubility:

• DMSO: ~20 mg/mL (freely soluble)
• DMF: ~10 mg/mL
• Ethanol: ~0.25 mg/mL
• 1:3 DMSO:PBS (pH 7.2): ~0.25 mg/mL
• Water (neat): Poorly soluble

Solutions prepared at pH 4-6 demonstrate enhanced stability compared to neutral or alkaline pH. The tyrosine residue in dihexa's structure is susceptible to oxidation, so reducing agents such as ascorbic acid and methionine are sometimes added to protect against degradation during storage. As a lyophilized powder, dihexa should be stored at -20 degrees C; reconstituted solutions require refrigeration at 2-8 degrees C.

Pharmacokinetic Properties#

Dihexa is one of very few peptide-derived compounds with meaningful oral bioavailability. In rat studies, approximately 38% of orally administered compound reached systemic circulation -- remarkably high for a peptide derivative. Studies using radiolabeled dihexa confirmed brain penetration across multiple regions, supporting the behavioral data from Morris water maze experiments. However, the exact plasma half-life has never been published, and comprehensive metabolic pathway mapping has not been reported in the literature.

The Retracted Paper Controversy#

The retraction of Benoist et al. (2014) is the defining event in dihexa's research history. Understanding what happened -- and what it means for the remaining evidence -- is essential for anyone evaluating this compound.

What the Paper Claimed#

The 2014 study, titled "The Procognitive and Synaptogenic Effects of Angiotensin IV-Derived Peptides Are Dependent on Activation of the Hepatocyte Growth Factor/c-Met System," was published in the Journal of Pharmacology and Experimental Therapeutics (originally PMID: 25187433). It provided the key mechanistic evidence linking dihexa's cognitive enhancement effects specifically to HGF/c-Met pathway activation. The paper reported that dihexa-induced synaptogenesis was blocked by HGF-neutralizing antibodies and c-Met inhibitors, establishing the causal chain between the compound, HGF/c-Met signaling, and neuronal connectivity.

What the Investigation Found#

In 2021, four papers from the Harding/Wright laboratory at Washington State University received expressions of concern from the journal after allegations of image manipulation surfaced. The investigation centered on Leen Kawas, who had been a PhD student under Harding and later became CEO of Athira Pharma, a biotech company that developed a related compound (fosgonimeton/ATH-1017) as its lead Alzheimer's candidate.

A special committee investigation at WSU found that Kawas had systematically altered images in her 2011 doctoral dissertation and in at least four co-authored research papers published between 2011 and 2014. Specifically for the Benoist et al. paper, figures 1B and 2A/C and associated data were found to contain falsified and/or fabricated elements.

Consequences#

The fallout was substantial:

• Paper retracted: The Benoist et al. (2014) study was formally retracted in April 2025.
• PhD revoked: Washington State University revoked Kawas's doctorate.
• CEO resignation: Kawas resigned as CEO of Athira Pharma in October 2021.
• Securities settlement: Athira paid $10 million in February 2023 to settle securities fraud class-action lawsuits.
• Patent implications: WSU's dihexa patent incorporates images from the papers co-authored by Kawas, some of which were found to be altered.

What Remains Valid#

The retraction does not invalidate all dihexa research. Two key studies remain unretracted:

1. McCoy et al. (2013) (PMID: 23055539) -- the foundational characterization demonstrating oral bioavailability, BBB permeability, and cognitive enhancement in aged rats. While several co-authors overlap with the retracted paper (including Harding), this study has not been challenged.

2. Sun et al. (2021) (PMID: 34827486) -- an independent study from a Chinese research group demonstrating cognitive rescue in APP/PS1 Alzheimer's model mice through PI3K/AKT pathway activation.

However, the retraction removes the primary evidence that dihexa's effects are specifically mediated through HGF/c-Met. The Sun et al. study identified PI3K/AKT signaling as the relevant pathway -- a related but distinct mechanism. The question of whether dihexa truly works through HGF modulation, or through some other mechanism, remains open.

HGF/c-Met: Mechanism and Oncogenic Concerns#

The proposed mechanism of action for dihexa -- potentiation of hepatocyte growth factor at its c-Met receptor -- is both what makes the compound scientifically interesting and what makes it potentially dangerous.

How It Is Supposed to Work#

Dihexa binds to HGF with high affinity and augments HGF's ability to activate the c-Met receptor tyrosine kinase at subthreshold concentrations. At picomolar to nanomolar concentrations, dihexa potentiates HGF-dependent c-Met phosphorylation, promoting downstream signaling through PI3K/AKT pathways that drive synaptogenesis and neuronal survival. Notably, dihexa does not independently activate c-Met -- it requires the presence of endogenous HGF to produce its effects.

At micromolar concentrations, the relationship reverses: dihexa inhibits HGF dimerization, suggesting a biphasic, concentration-dependent interaction. This allosteric modulation of a growth factor (rather than direct receptor agonism) is pharmacologically distinctive but also complicates safety assessment.

The Cancer Pathway Problem#

The c-Met/HGF signaling axis is one of the most extensively studied oncogenic pathways in cancer biology. Dysregulated c-Met signaling drives tumor growth, invasion, metastasis, and angiogenesis across multiple cancer types including lung, liver, gastric, breast, and renal carcinomas. The pharmaceutical industry has invested billions in developing c-Met inhibitors precisely because this pathway is a validated cancer driver:

• Capmatinib (FDA-approved 2020) -- selective MET inhibitor for non-small cell lung cancer
• Tepotinib (FDA-approved 2021) -- selective MET inhibitor for NSCLC with METex14 skipping mutations

Dihexa activates the same pathway these drugs are designed to block. While potentiation of subthreshold HGF (as dihexa does) is mechanistically different from constitutive c-Met activation (as seen in cancer), no carcinogenicity studies have been conducted to determine whether chronic HGF pathway potentiation promotes neoplastic transformation. A dihexa-related patent notes that "short duration safety studies with dihexa have uncovered no apparent toxicity" regarding neoplastic induction, but short-duration studies in rodents are insufficient to evaluate long-term oncogenic risk.

The Clinical Pipeline: From Dihexa to Fosgonimeton to Failure#

Dihexa itself (PNB-0408) has never entered human clinical trials. However, the same Washington State University research produced a related compound that reached the clinic.

Athira Pharma and Fosgonimeton (ATH-1017)#

M3 Biotechnology, co-founded by Harding and Kawas, rebranded as Athira Pharma and developed fosgonimeton (ATH-1017), a prodrug that converts to the active metabolite ATH-1001 in vivo. ATH-1001 also targets the HGF/MET neurotrophic system, making fosgonimeton a clinical-stage descendant of the dihexa research program.

Athira went public in September 2020 at $17 per share, raising $204 million, and advanced fosgonimeton through multiple clinical trials:

• Phase 1: Published results (PMID: 35180125) showed safety and tolerability in healthy volunteers with evidence of CNS penetration.
• ACT-AD (Phase 2): Proof-of-concept study in mild-to-moderate Alzheimer's disease. Results showed biomarker signals but limited clinical improvement.
• LIFT-AD (Phase 2/3): The pivotal trial in mild-to-moderate Alzheimer's disease. In September 2024, Athira announced that LIFT-AD failed to meet its primary endpoint (improvement on the Global Statistical Test) after 26 weeks of treatment.
• SHAPE (Phase 2): Parkinson's disease dementia/Lewy body dementia trial. Enrollment was ended early at 28 subjects in October 2022 due to study design limitations. The primary endpoint was not met.

Aftermath#

Following the LIFT-AD failure, Athira laid off approximately 70% of its workforce and paused all fosgonimeton development, including the open-label extension study. The company subsequently pivoted entirely away from neuroscience, licensing lasofoxifene (a breast cancer treatment) and rebranding as LeonaBio in January 2026 under the new ticker LONA.

The clinical failure of fosgonimeton does not directly prove that dihexa is ineffective -- they are different compounds with different pharmacokinetics. However, it does demonstrate that the broader HGF/c-Met potentiation strategy for neurodegenerative disease has not yet produced clinical evidence of efficacy, despite reaching Phase 2/3 testing.

Current Research Landscape#

As of early 2026, the dihexa research landscape is sparse.

What Is Still Being Investigated#

The only fully independent published study of dihexa remains the Sun et al. (2021) work in APP/PS1 mice. This study is important because it was conducted by a research group with no connection to the Washington State University team and provides corroborating evidence for dihexa's cognitive-enhancing effects through an independently identified mechanism (PI3K/AKT signaling rather than the now-questionable HGF/c-Met pathway).

The compound continues to be available as a research chemical from chemical suppliers (Selleck, MedChemExpress, Cayman Chemical, among others) for in vitro and animal studies. It is catalogued in PubChem (CID 125355097) and is recognized by the FDA's Global Substance Registration System. No new animal studies or mechanistic investigations have appeared in PubMed since the Sun et al. 2021 publication.

What Is Not Happening#

• No human clinical trials for dihexa (PNB-0408) are registered on ClinicalTrials.gov
• No independent research group has attempted to replicate the HGF/c-Met-specific mechanism
• No carcinogenicity or genotoxicity studies have been conducted
• No comprehensive pharmacokinetic profiling (half-life, metabolic pathways, tissue distribution) has been published
• The related clinical program (fosgonimeton) has been abandoned

The "10 Million Times More Potent Than BDNF" Claim#

This widely circulated claim deserves scrutiny. It originates from a specific in vitro neurotrophic assay comparing dihexa's activity at picomolar concentrations to BDNF. While the measurement itself may be technically accurate within the constraints of that assay, the comparison is misleading. Dihexa and BDNF work through entirely different receptors and signaling pathways, the assay measures a narrow endpoint that does not represent overall neurotrophic efficacy, and potency in an in vitro assay does not translate to comparative effectiveness in a living organism. This claim has become a marketing artifact that circulates far beyond its original scientific context.

Safety Considerations#

The safety profile of dihexa is essentially unknown. The compound has never been tested in humans, and no systematic toxicology program has been conducted.

Known and Theoretical Risks#

Regulatory Status#

Dihexa is not a controlled substance in any major jurisdiction. It is not FDA-approved, not MHRA-approved, not EMA-approved, and not authorized for human therapeutic use anywhere in the world. It is available as a research chemical for laboratory use. In the United States, the FDA's 2024 Category 2 bulk drug substance review process has not specifically addressed dihexa, as it has not been nominated for compounding pharmacy use.

Key Takeaways#

The evidence base is thin and partially compromised. Two unretracted preclinical studies show cognitive enhancement in rodents. The primary mechanistic study linking these effects to HGF/c-Met activation has been retracted due to data fabrication.

The clinical pipeline is dead. The related compound fosgonimeton failed its pivotal Phase 2/3 trial for Alzheimer's disease, and its developer has exited neuroscience entirely.

The oncogenic safety question is unanswered. Dihexa activates a pathway that multiple FDA-approved drugs are designed to inhibit because of its role in driving cancer. No carcinogenicity studies have been conducted.

Independent replication is minimal. Only one independent study (Sun et al., 2021) has corroborated dihexa's cognitive effects, and it identified a different signaling mechanism (PI3K/AKT) than the now-retracted HGF/c-Met evidence.

Chemical properties are well-characterized. The compound's structure, solubility, oral bioavailability, and BBB permeability are the most robust aspects of the evidence base, originating from the unretracted McCoy et al. (2013) foundational study.

For researchers evaluating dihexa, the compound represents an interesting pharmacological concept -- an orally bioavailable peptidomimetic that enhances neurotrophic signaling at picomolar concentrations. But the scientific foundations have been significantly damaged by the retraction, the clinical validation attempt has failed, and the fundamental safety question of chronic oncogenic pathway activation remains entirely unanswered.

References#

• McCoy AT, Benoist CC, Wright JW, et al. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. J Pharmacol Exp Ther. 2013;344(1):141-154. PMID: 23055539.
• Sun X, Deng Y, Fu X, et al. AngIV-analog dihexa rescues cognitive impairment and recovers memory in the APP/PS1 mouse via the PI3K/AKT signaling pathway. Brain Sci. 2021;11(11):1487. PMID: 34827486.
• Benoist CC, Kawas LH, Zhu M, et al. [RETRACTED] The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-Met system. J Pharmacol Exp Ther. 2014;351(2):390-402. Originally PMID: 25187433. Retracted April 2025.
• Hua X, Church K, Walker W, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the positive modulator of HGF/MET, fosgonimeton, in healthy volunteers and subjects with Alzheimer's disease. J Alzheimers Dis. 2022;87(3):1399-1413. PMID: 35180125.

Related Peptide Profiles#

Learn more about the peptides discussed in this article:

• Dihexa Overview and Research Guide
• Dihexa Molecular Structure and Properties
• Dihexa Research Studies and Evidence
• Dihexa Risks, Warnings, and Legal Status
• Semax Overview and Research Guide
• Cerebrolysin Overview and Research Guide